Addictive disorders: Edited by John B. Saunders and Linda B. CottlerLong-acting depot formulations of naltrexone for heroin dependence: a reviewKrupitsky, Evgeny Ma,b; Blokhina, Elena AaAuthor Information aLaboratory of Clinical Psychopharmacology of Addictions, Valdman Institute of Pharmacology, St Petersburg State Pavlov Medical University, Russia bDepartment of Addictions, St Petersburg Bekhterev Research Psychoneurological Institute, St Petersburg, Russia Correspondence to Evgeny M. Krupitsky, MD, PhD, DMedSci, Chief, Department of Addictions, St Petersburg Bekhterev Research Psychoneurological Institute, Bekhtereva Street 3, St Petersburg 192019, Russia Tel: +7 812 296 9905; fax: +7 812 365 2217; e-mail: firstname.lastname@example.org@gmail.com Current Opinion in Psychiatry: May 2010 - Volume 23 - Issue 3 - p 210-214 doi: 10.1097/YCO.0b013e3283386578 Buy Metrics Abstract Purpose of review The major problem with the oral formulation of naltrexone for heroin dependence is poor compliance (adherence). Long-acting sustained release formulations of naltrexone (implantable and injectable) might help to improve compliance and, thus, increase the efficacy of abstinence-oriented treatment of heroin dependence with naltrexone. Recent findings There have been several implantable and injectable formulations of naltrexone developed within the last decade. It was demonstrated that some of them are effective and relatively well tolerated medications for relapse prevention in heroin addicts. However, advantages and disadvantages of these new medications have never been systematically analyzed. Summary Long-acting sustained release formulations of naltrexone are well tolerated and more effective for relapse prevention in heroin addicts than the oral ones. © 2010 Lippincott Williams & Wilkins, Inc.